FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)

View source ↗

Summary

FDA approves a supplemental application for Juxtapid (lomitapide mesylate) by Amryt Pharmaceuticals DAC, resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• JUXTAPID (lomitapide)

Snippet

SUPPL AP for JUXTAPID (LOMITAPIDE MESYLATE)